Panelists discuss how recent advancements in treatment strategies for ALK-positive and BRAF-positive V600E NSCLC, including efficacy updates and the management of brain metastases, can enhance personalized care and optimize patient outcomes.
October 25th 2024
Panelists discuss the importance of molecular testing in NSCLC, particularly for ALK rearrangements, and explore how recent advancements and emerging technologies are shaping first-line treatment selection for ALK-positive patients.
Panelists discuss the key findings from the latest data from the CROWN and BRIGHTSTAR studies, emphasizing efficacy end points and comparing the effectiveness of these regimens with that of others in the treatment landscape for ALK-positive NSCLC.
November 1st 2024
Panelists discuss how recent data influence treatment choices for ALK-positive NSCLC patients, highlighting specific patient factors that guide decisions and potential concerns regarding the use of lorlatinib as first-line therapy.
Panelists discuss the circumstances under which they would consider switching patients on different first-line treatments to lorlatinib and outline approaches for CNS surveillance and management in ALK-positive patients.
November 8th 2024
Panelists discuss the efficacy of ALK inhibitors in treating brain metastases, referencing data from the REMARK study, the CROWN trial, ALTA-3, and ALTA-1L/brigatinib, among others.
Panelists discuss the findings from the ALINA study on adjuvant alectinib vs chemotherapy in resected ALK-positive NSCLC, considering how these results may influence early-stage management, sequencing strategies for ALK inhibitors, and the role of resistance mechanisms in treatment decisions.